RFK Jr. Fills FDA Advisory Panel With Peptide Sellers Amid Scientist Opposition

Robert F. Kennedy Jr. has appointed members to an FDA advisory panel who are associated with selling peptide drugs. FDA scientists have raised concerns, warning that these peptide compounds remain largely untested and could pose health risks. The move has sparked internal opposition within the agency from its own scientific staff. The appointments raise questions about potential conflicts of interest influencing federal drug oversight policy.